Nasal Drug Delivery

SNBL’s nasal drug delivery platform is a proprietary system consisting of powder carrier technology and delivery device technology.

Expertise in Nasal Delivery

3D Nasal Cast Model



SNBL seeks to establish strategic partnership of our nasal drug delivery technology with pharmaceutical companies. After conducting a evaluation program to fulfill client’ s needs, as shown as below, we would license our technology (e.g. by compound, indication, area of application, nation/region, etc.).

Licensee of Platform Technology

Satsuma Pharmaceuticals, Inc. (USA)

Satsuma Pharmaceuticals, Inc. (Satsuma) was established in the US by SNBL primarily for the purpose of furthering the development of a migraine treatment drug (dihydroergotamine, DHE) applying SNBL licensing platform technology related to the development of nasal DHE products (STS101). 


On April 24, 2019, Satsuma announced a $62 million Series-B preferred stock financing led by Wellington Management Company with participation by existing investors and new investors. Financing proceeds will support Phase 3 development of STS101. Satsuma plans to initiate its Phase 3 clinical trial in the third quarter of 2019 (Jul – Sep).


Satsuma plans to develop, obtain regulatory approval for, and potentially commercialize STS101.  Satsuma believes STS101, with generation of positive clinical study results, may attract licensing and acquisition interest from larger pharmaceutical companies.  At an appropriate time, Satsuma anticipates exploring such potential licensing and acquisition opportunities, as well as potential public stock listing and/or offering options.